


U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <b>NAKAJIMA 7</b>
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (if known see 37 CFR 1.5) <b>10/571199</b>
INTERNATIONAL APPLICATION NO. <b>PCT/JP2005/013950</b>	INTERNATIONAL FILING DATE <b>July 29, 2005</b>	PRIORITY CLAIMED <b>August 3, 2004</b>
TITLE OF INVENTION <b>PSYCHOTROPIC AGENT, ANALGESIC AGENT AND/OR ANTIINFLAMMATORY AGENT, AND HEALTH FOOD CONTAINING BENZYLISOQUINOLINE OR BISBENZYLISOQUINOLINE DERIVATIVE</b>		
APPLICANT(S) FOR DO/EO/US <b>Hiroshi NAKAJIMA et al.</b>		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li><input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li><input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f) ) as soon as the application is in order for such purpose and the applicable requirements of 35 U.S.C. 371(c) have been complied with.</li> <li><input type="checkbox"/> The US has been elected (Art 31).</li> <li><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))             <ol style="list-style-type: none"> <li><input type="checkbox"/> is attached hereto (required only if not transmitted by the International Bureau).</li> <li><input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li><input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li><input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).             <ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> is attached hereto.</li> <li><input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li><input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))             <ol style="list-style-type: none"> <li><input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li><input type="checkbox"/> have been communicated by the International Bureau.</li> <li><input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li><input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li><input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li><input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li><input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol> <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> <li><input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li><input type="checkbox"/> An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li><input checked="" type="checkbox"/> A FIRST preliminary amendment.</li> <li><input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</li> <li><input type="checkbox"/> A substitute specification.</li> <li><input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li><input type="checkbox"/> A computer-readable sequence form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.</li> <li><input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</li> <li><input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4)</li> <li><input checked="" type="checkbox"/> Other items or information:             <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Courtesy copy of the first page of the International Publication (WO 2006/013792 A1).</li> <li><input checked="" type="checkbox"/> Courtesy Copy of the International Search Report.</li> <li><input checked="" type="checkbox"/> The application is (or will be) assigned to: EDUCATION CENTER OF TRADITIONAL CHINESE MEDICINE CO. whose address is 3-14, Nishitemma 2-chome, Kita-ku, Osaka-shi, Osaka 530-0047, Japan.</li> </ul> </li> </ol>		

U.S. APPLICATION NO. (if known see 37 CFR 1.51) <b>10/571199</b>		International Application No. <b>PCT/JP2005/013950</b>		Attorney's Docket No. <b>NAKAJIMA 7</b>	
21. The following fees are submitted:				<b>CALCULATIONS PTO USE ONLY</b>	
<b>[xx] a) BASIC NATIONAL FEE (37 CFR 1.492(a)).....\$300.00</b>					
<b>[xx] b) SEARCH FEE (37 CFR 1.492(b))</b>					
<input type="checkbox"/> US was International Searching Authority.....\$100.00					
<b>[xx] Other ISR provided to USPTO.....\$400.00</b>					
<input type="checkbox"/> All other situations.....\$500.00				\$900.00	
<b>[xx] c) EXAMINATION FEE (37 CFR 1.492 (c))</b>					
<input type="checkbox"/> IPEA/US gave wholly favorable IPER.....\$100.00					
<b>[xx] All other situations.....\$200.00</b>					
<b>TOTAL OF ABOVE CALCULATIONS :</b>					
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(h)).				\$	
<b>TOTAL SHEETS</b>		<b>EXTRA SHEETS</b>		<b>Number of each additional 50 or fraction thereof (round up to a whole number)</b>	
89 - 100		/50		RATE (1.492(g))	
				X \$250.00	
<b>CLAIMS</b>		<b>Number Filed</b>		<b>Number Extra</b>	
Total Claims		5 - 20 =		Rate (1.492 (d-f))	
Independent Claims		1 - 3 =		X \$ 50.00	
Multiple Dependent Claims (if applicable)				X \$200.00	
				+ \$360.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$900.00	
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27.				\$	
<b>SUBTOTAL =</b>				\$900.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$900.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$900.00	
				<b>Amount to be:</b>	
				<b>refunded</b>	
				<b>charged</b>	
<b>Payment Method (check one only)</b>					
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.					
b. <input checked="" type="checkbox"/> Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$900.00, is attached.					
c. <input type="checkbox"/> Please charge my Deposit Account No. <b>02-4035</b> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
<b>Handling of Fee Deficiencies (check one only)</b>					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <b>02-4035</b> . A duplicate copy of this sheet is enclosed.					
<input type="checkbox"/> If a deficiency exists in the basic national fee set by 37 CFR 1.492(a), please charge it to Deposit Account <b>02-4035</b> . At this time, no authorization is given to charge any other fees.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
Direct all correspondence to the address associated with <b>CUSTOMER NUMBER 001444</b> , which is currently:					
<b>BROWDY AND NEIMARK, P.L.L.C.</b> <b>624 NINTH STREET, N.W., SUITE 300</b> <b>WASHINGTON, D.C. 20001</b> <b>TEL: (202) 628-5197</b> <b>FAX: (202) 737-3528</b> <b>Date of this submission: March 9, 2006</b>					
				 <b>SIGNATURE</b> <b>Roger L. Browdy</b> <b>NAME</b> <b>25,618</b> <b>REGISTRATION NUMBER</b>	
				<b>RLB:lmh</b>	